High-Throughput Spheroid Screening Platform

Information

  • Research Project
  • 9847707
  • ApplicationId
    9847707
  • Core Project Number
    R44GM134806
  • Full Project Number
    1R44GM134806-01
  • Serial Number
    134806
  • FOA Number
    PA-18-574
  • Sub Project Id
  • Project Start Date
    9/9/2019 - 6 years ago
  • Project End Date
    8/31/2021 - 4 years ago
  • Program Officer Name
    SAMMAK, PAUL J
  • Budget Start Date
    9/9/2019 - 6 years ago
  • Budget End Date
    8/31/2020 - 5 years ago
  • Fiscal Year
    2019
  • Support Year
    01
  • Suffix
  • Award Notice Date
    9/9/2019 - 6 years ago
Organizations

High-Throughput Spheroid Screening Platform

PROJECT SUMMARY This proposal will develop the High-Throughput Spheroid Screening Platform (HTSSP) to create an entirely new tool to study cell-cell interactions and microenvironmental stresses that occur in tissues and tumors. Such interactions are critical in the pharmaceutical response of cells within tissues, but current methods do not allow high throughput screening (HTS) of cellular responses in a tissue-like microenvironment. The HTSSP is being developed to enable the use of the powerful multicellular spheroid 3D tissue/tumor model system, which has many potential applications in 3D drug screening, in true high-throughput screening (HTS) applications. To create the HTSSP, we are addressing critical limitations in large particle analysis via flow cytometry (Aim 1), continuous sample handling of large particles such as spheroids (Aim 2), improving analytical methods to obtain spatial/structural information from spheroids in analysis (Aim 3), and demonstrating key applications of the HTSSP in real world assays (Aim 4). To improve flow cytometry analysis, we will optimize our current high throughput parallel flow cytometer (the 10xFC) by modifying the flow cells and the optics for ideal use with particles between 100 and 1000 microns in diameter. This flow cytometer will be integrated with an innovative suspension culture and sampling fluidic system to create the hardware of the HTSSP. These fluidics will maintain multiple samples of spheroids in stirred suspension chambers during incubation or exposure to drugs, then use the same chambers for sampling and resampling for analysis by our flow cytometer. The final synergistic technical achievement will be the development of improved data acquisition systems that enable the rapid extraction of 3D location information from probes within a spheroid. When combined with the hardware, this will synergistically complete the HTSSP, which will be used for key high-throughput pharmaceutical screening applications, including: apoptosis/necrosis induction, fraction of each cell type in a co-culture, fluorescent drug uptake. Taken as a whole, the HTSSP will represent a significant technological advance in pharmaceutical screening as it will provide the first truly high throughput approach to the study of pharmaceutical interactions in a 3D tissue model.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R44
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    499717
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    859
  • Ed Inst. Type
  • Funding ICs
    NIGMS:499717\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    BENNUBIO INC
  • Organization Department
  • Organization DUNS
    081189884
  • Organization City
    ALBUQUERQUE
  • Organization State
    NM
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    871022334
  • Organization District
    UNITED STATES